Researchers find protein marker for the effectiveness of malaria antibodies

The quantity and quality of antibodies that recognize the end region of the malaria parasite’s CSP protein is a good marker of protection by the RTS,S/AS01E vaccine, according to a study led by the Barcelona Institute for Global Health (ISGlobal) and institutional collaborators. The study, published in Nature Communications, provides valuable information for guiding the design of more effective vaccines. […]

Read more

Cocaine deaths up in US, and opioids are a big part of it

U.S. health officials say cocaine overdose deaths have been rising. Drug overdose deaths involving cocaine began rising around 2012, and jumped 34 percent between 2016 and 2017. The Centers for Disease Control and Prevention released the report Thursday. The increase at least partly reflects trends in deaths from heroin, fentanyl and other opioid drugs. Many overdose deaths involve someone who […]

Read more

Poll: Many blame drug firms for opioid crisis

About two-thirds of Americans believe drug companies are to blame for the opioid crisis, although nearly as many hold drug users themselves responsible, a new poll finds. The Associated Press-NORC Center for Public Affairs Research poll showed many people also fault doctors who prescribed opioid pain pills and government officials who haven’t done enough to expand addiction treatment and arrest […]

Read more

New drug mimics benefits of ketamine for depression

A new small-molecule drug produced a rapid antidepressant response similar to that of ketamine when tested in mice, a new Yale-led study published April 16 in the Journal of Clinical Investigation shows. The effects of the drug, called NV-5138, in rodent models mimicked the rapid actions of the anesthetic ketamine, a variation of which, Esketamine, was recently approved by the […]

Read more

High-dose, immune-boosting or four-strain? A guide to flu vaccines for over-65s

Flu vaccines work by exposing the body to a component of the virus so it can “practise” fighting it off, without risking infection. The immune system can then mount a more rapid and effective response when faced with a “real” virus. Three types of influenza vaccines are available in Australia: “standard” vaccines that contains four different strains of influenza a […]

Read more

Why Australians are using painkillers for social and emotional suffering

George (Kev) Dertadian has always been interested in challenging the stigmatisation of drug users. The UNSW Criminology Lecturer and social researcher’s fascination with this field of research started when he read a paper by UNSW academics Professor Lisa Maher and Professor David Dixon on the cost of drug crackdowns in Cabramatta. “They found that when you crack down on communities […]

Read more

Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1

1 April 2019 AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the investigational MEK 1/2 inhibitor and potential new medicine selumetinib. This designation is for the treatment of pediatric patients aged three years and […]

Read more

Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

Brussels, Belgium – 2 March 2019 – UCB, a global biopharmaceutical company, presented positive data from the Phase 2b BE ABLE extension study of bimekizumab in patients with moderate-to-severe chronic plaque psoriasis, which showed nearly all BE ABLE 1 responders completing 60 weeks of bimekizumab treatment maintained complete or almost complete skin clearance. The results are the longest-term data so […]

Read more

FDA Approves Adhansia XR

STAMFORD, Conn.–(BUSINESS WIRE) March 01, 2019 –Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII, a central nervous system (CNS) stimulant, for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients six years and older. In a simulated Adult Workplace Environment (AWE) study, Adhansia […]

Read more

FDA Approves Esperoct

Bagsværd, Denmark, 19 February 2019 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for Esperoct for the treatment of adults and children with hemophilia A. Esperoct is the brand name for turoctocog alfa pegol, N8-GP. Esperoct is indicated for use in adults and children with hemophilia A (congenital factor […]

Read more
1 2 3 6